LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Thursday. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.17, Bloomberg Earnings reports. The firm had revenue of $309.70 million for the quarter, compared to analysts’ expectations of $301.22 million. LivaNova PLC had a net margin of 2.26% and a return on equity of 9.08%. The business’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 EPS. LivaNova PLC updated its FY17 guidance to $3.30-3.45 EPS.
Several research analysts have weighed in on LIVN shares. WBB Securities cut shares of LivaNova PLC from a “hold” rating to a “sell” rating and set a $50.00 price target on the stock. in a report on Tuesday, August 15th. BidaskClub cut shares of LivaNova PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Piper Jaffray Companies reissued an “overweight” rating and issued a $75.00 price target on shares of LivaNova PLC in a report on Tuesday, September 12th. Needham & Company LLC started coverage on shares of LivaNova PLC in a report on Wednesday, August 23rd. They issued a “hold” rating on the stock. Finally, Canaccord Genuity reissued a “hold” rating and issued a $71.00 price target on shares of LivaNova PLC in a report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. LivaNova PLC has an average rating of “Hold” and an average target price of $71.50.
In other LivaNova PLC news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova PLC stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $68.55, for a total value of $68,550.00. Following the sale, the director now owns 57,296 shares of the company’s stock, valued at $3,927,640.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 3,000 shares of company stock worth $203,890. Insiders own 0.28% of the company’s stock.
LivaNova PLC Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
What are top analysts saying about LivaNova PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LivaNova PLC and related companies.